Plain-English translation of NCT06733935 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a new type of therapy that uses specially engineered immune cells called natural killer cells to help treat autoimmune diseases. The medication works by targeting and reducing a specific type of B cell that contributes to autoimmune problems. Researchers want to see if this approach is safe and whether it can help people with systemic sclerosis, inflammatory muscle diseases, vasculitis, or rheumatoid arthritis.
Current treatments for these autoimmune diseases don't work well enough for everyone, and some people can't tolerate them. This trial is exploring whether this new cell-based approach could offer a better option for people whose disease hasn't improved with standard treatments.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will first receive chemotherapy drugs ( and ) to prepare your body, then receive three doses of the new therapy. The study will monitor you closely with blood tests, imaging, and clinic visits to check how well the treatment works and watch for any side effects. The trial is still recruiting, so the exact schedule and duration would be discussed with the research team at your first visit.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States